38 related articles for article (PubMed ID: 8758798)
1. Real-time monitoring ATP variation in human cancer organoids for a long term by DNA-based nanosensor.
Zhang K; Wang Y; Xue J; Liang N; Wei Z
Anal Chim Acta; 2023 Sep; 1275():341608. PubMed ID: 37524457
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
3. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
4. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
5. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
6. [Application of a micromethod in ovarian cancer chemosensitivity testing in vitro].
Liu S; Qian X; Peng Z; Wang H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):298-9, 312. PubMed ID: 12947719
[TBL] [Abstract][Full Text] [Related]
7. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.
Kurbacher CM; Cree IA
Methods Mol Med; 2005; 110():101-20. PubMed ID: 15901931
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitivity and chemoresistance testing in ovarian cancer.
Cree IA
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002
[TBL] [Abstract][Full Text] [Related]
10. [Flow cytometric BrdU/DNA assay for anticancer agent sensitivity test].
Katayanagi N; Suzuki T; Tanaka O; Muto T
Nihon Rinsho; 1992 Oct; 50(10):2386-90. PubMed ID: 1280306
[TBL] [Abstract][Full Text] [Related]
11. [Chemosensitivity testing in ovarian cancer--prospects for the future].
Pogońska P; Wydra D; Serkies K; Kobierski J; Łojkowska A
Ginekol Pol; 2014 Sep; 85(9):695-8. PubMed ID: 25322542
[TBL] [Abstract][Full Text] [Related]
12. [Cancer chemosensitivity test--from laboratory to clinic].
Kubota T
Hum Cell; 1995 Dec; 8(4):189-94. PubMed ID: 8721090
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
